| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1196 | 2019 |
| Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer D Lodygin, V Tarasov, A Epanchintsev, C Berking, T Knyazeva, H Körner, ... Cell cycle 7 (16), 2591-2600, 2008 | 956 | 2008 |
| From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression O Schmidt-Kittler, T Ragg, A Daskalakis, M Granzow, A Ahr, ... Proceedings of the National Academy of Sciences 100 (13), 7737-7742, 2003 | 801 | 2003 |
| Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives J Mazières, S Peters, B Lepage, AB Cortot, F Barlesi, M Beau-Faller, ... Journal of clinical oncology 31 (16), 1997-2003, 2013 | 779 | 2013 |
| Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort J Mazières, G Zalcman, L Crinò, P Biondani, F Barlesi, T Filleron, ... Journal of clinical oncology 33 (9), 992-999, 2015 | 429 | 2015 |
| Functional epigenomics identifies genes frequently silenced in prostate cancer D Lodygin, A Epanchintsev, A Menssen, J Diebold, H Hermeking Cancer research 65 (10), 4218-4227, 2005 | 380 | 2005 |
| Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ... Journal of Clinical Oncology 35 (13), 1403-1410, 2017 | 369 | 2017 |
| Inheritance of gene density–related higher order chromatin arrangements in normal and tumor cell nuclei M Cremer, K Küpper, B Wagler, L Wizelman, J Hase, Y Weiland, L Kreja, ... The Journal of cell biology 162 (5), 809-820, 2003 | 350 | 2003 |
| Apoptosis and immunohistochemical bcl‐2 expression in colorectal adenomas and carcinomas: Aspects of carcinogenesis and prognostic significance GB Baretton, J Diebold, G Christoforis, M Vogt, C Müller, K Dopfer, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 1996 | 332 | 1996 |
| Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer N Anand, S Murthy, G Amann, M Wernick, LA Porter, IH Cukier, C Collins, ... Nature genetics 31 (3), 301-305, 2002 | 325 | 2002 |
| KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants D Mayr, A Hirschmann, U Löhrs, J Diebold Gynecologic oncology 103 (3), 883-887, 2006 | 291 | 2006 |
| The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop A Menssen, P Hydbring, K Kapelle, J Vervoorts, J Diebold, B Lüscher, ... Proceedings of the National Academy of Sciences 109 (4), E187-E196, 2012 | 286 | 2012 |
| IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression S Brand, F Beigel, T Olszak, K Zitzmann, ST Eichhorst, JM Otte, J Diebold, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 289 (5 …, 2005 | 279 | 2005 |
| How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast-and Gynecopathologists Z Varga, J Diebold, C Dommann-Scherrer, H Frick, D Kaup, A Noske, ... PloS one 7 (5), e37379, 2012 | 274 | 2012 |
| CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation S Brand, J Dambacher, F Beigel, T Olszak, J Diebold, JM Otte, B Göke, ... Experimental cell research 310 (1), 117-130, 2005 | 270 | 2005 |
| Targeted therapy for patients with BRAF-mutant lung cancer results from the European EURAF cohort O Gautschi, J Milia, B Cabarrou, MV Bluthgen, B Besse, EF Smit, J Wolf, ... Journal of Thoracic Oncology 10 (10), 1451-1457, 2015 | 213 | 2015 |
| bcl-2 Expression, p53 Accumulation, and Apoptosis in Ovarian Carcinomas J Diebold, G Baretton, M Felchner, W Meier, K Dopfer, M Schmidt, U Löhrs American journal of clinical pathology 105 (3), 341-349, 1996 | 202 | 1996 |
| Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate J Engel, R Eckel, G Schubert-Fritschle, J Kerr, W Kuhn, J Diebold, ... European Journal of Cancer 38 (18), 2435-2445, 2002 | 192 | 2002 |
| Photodynamic therapy of vulvar intraepithelial neoplasia using 5‐aminolevulinic acid P Hillemanns, M Untch, C Dannecker, R Baumgartner, H Stepp, J Diebold, ... International journal of cancer 85 (5), 649-653, 2000 | 192 | 2000 |
| A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib O Gautschi, C Pauli, K Strobel, A Hirschmann, G Printzen, S Aebi, ... Journal of Thoracic Oncology 7 (10), e23-e24, 2012 | 173 | 2012 |
Stefan AebiMedical Oncology, Cancer Center Lucerne Cantonal Hospital, and University of BerneBestätigte E-Mail-Adresse bei onkologie.ch
